Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003105 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00003105: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003105 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003105, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients with metastatic or locally advanced bladder cancer.
Interventions
- DRUG cisplatin
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1997-09 |
| Est. Completion | 2004-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003105
The ClinicalTrials.gov registry entry for NCT00003105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003105 about?
NCT00003105 is a clinical study titled "Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients with metastatic or lo...
What is the current status of trial NCT00003105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1997-09. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00003105?
The interventions under investigation include: cisplatin (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003105?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.